SHSE:600276'
s ROA % Range Over the Past 10 Years
Min: 9.57 Med: 16.68 Max: 21.28
Current: 12.54
During the past 13 years, Jiangsu Hengrui Pharmaceuticals Co's highest ROA % was 21.28%. The lowest was 9.57%. And the median was 16.68%.
SHSE:600276's ROA % is ranked better than 88.73% of 1003
companies
in the Drug Manufacturers industry
Industry Median: 2.69
vs SHSE:600276: 12.54
Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Jiangsu Hengrui Pharmaceuticals Co ROA % Related Terms
Jiangsu Hengrui Pharmaceuticals Co ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Hengrui Pharmaceuticals Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Hengrui Pharmaceuticals Co ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's ROA % distribution charts can be found below:
* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) has a ROA % of 12.93% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. This is 22% below median its historical median of 16.68. Over the past decade, Jiangsu Hengrui Pharmaceuticals Co's ROA % has ranged from 9.57 to 21.28. According to the industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #113 out of 1003 companies in the Drug Manufacturers industry, placing it in the top 11.3%.
Is Jiangsu Hengrui Pharmaceuticals Co's ROA % too high?
Jiangsu Hengrui Pharmaceuticals Co's current ROA % of 12.93% is 22% below median its 10-year median of 16.68. Over the past 10 years, this metric has ranged from a low of 9.57 to a high of 21.28. The Drug Manufacturers industry median ROA % is 2.69. Jiangsu Hengrui Pharmaceuticals Co's value of 12.93% is 380.7% above this industry median. Based on the distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #113 out of 1003 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jiangsu Hengrui Pharmaceuticals Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Hengrui Pharmaceuticals Co's ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #113 out of 1003 companies for ROA %. This places Jiangsu Hengrui Pharmaceuticals Co in the top 11% of its industry — outperforming the majority of peers. The industry median ROA % is 2.69. Jiangsu Hengrui Pharmaceuticals Co's value of 12.93% is 380.7% above this benchmark. Historically, Jiangsu Hengrui Pharmaceuticals Co's own ROA % has ranged from 9.57 to 21.28 over the past decade. While the company's 10-year median is 16.68 vs. the industry median of 2.69, Jiangsu Hengrui Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.69, based on 1,003 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Hengrui Pharmaceuticals Co's current ROA % of 12.93% is 380.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Hengrui Pharmaceuticals Co's current ROA % is 12.93%, which is 22% below median its own 10-year median of 16.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Hengrui Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥60.34, compared to a current price of ¥52.04 — trading 13.8% below its estimated fair value. The current ROA % is 12.93%, which is 22% below median its 10-year median of 16.68 and 380.7% above the Drug Manufacturers industry median of 2.69. Jiangsu Hengrui Pharmaceuticals Co's overall GF Score™ is 91/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276), the current ROA % is 12.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥52.04 is trading 13.8% below its estimated GF Value™ of ¥60.34.
GuruFocus considers Jiangsu Hengrui Pharmaceuticals Co to be Modestly Undervalued.
Key valuation signals for SHSE:600276:
ROA %: 12.93% (22% below median its 10-year median of 16.68)
GF Value™: ¥60.34 vs. price of ¥52.04 (13.8% below fair value)
Industry Position: 380.7% above the Drug Manufacturers median (#113 of 1003)
No single metric tells the full story. See the SHSE:600276 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Hengrui Pharmaceuticals Co Business Description
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
91GF Score
Get the complete analysis for SHSE:600276
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600276 has been successfully added to your 
